Lonidamine in primary malignant brain tumors. Preliminary report

C. M. Carapella, B. Iandolo, S. Delle Chiaie, A. Riccio

Research output: Contribution to journalArticlepeer-review


As part of a multicenter study on Lonidamine, this drug was studied in 16 patients with malignant gliomas. General and neurological examination, electroencephalography, electroneuromyography, and CT scan were repeated at regular intervals. The most common side effects were myalgia, nausea, and vomiting which usually subsided during treatment except in 4 patients. There was an indication of therapeutic activity in 4 out of 16 patients treated with Lonidamine.

Original languageEnglish
Pages (from-to)82-85
Number of pages4
Issue numberSUPPL. 1
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Lonidamine in primary malignant brain tumors. Preliminary report'. Together they form a unique fingerprint.

Cite this